Literature DB >> 33725976

PLCG2 as a potential indicator of tumor microenvironment remodeling in soft tissue sarcoma.

Zhengtian Li1, Rong Zhao1, Wenkang Yang1, Chan Li1, Jun Huang1, Zhenpei Wen1, Gang Du2, Lingling Jiang3.   

Abstract

ABSTRACT: The tumor microenvironment (TME) plays an important role in the occurrence and development of soft tissue sarcoma (STS). A number of studies have shown that to inhibit tumor growth, the TME can be remodeled into an environment unsuitable for tumor proliferation. However, a lack of understanding exists regarding the dynamic regulation of TME.In this study, we used CIBERSORT and ESTIMATE calculation methods from the Cancer Genome Atlas (TCGA) database to calculate the proportion of tumor infiltrating immune cells (TICs) and the number of immune and stromal components in 263 STS samples. Differential expression genes (DEGs) shared by Immune Score and Stromal Score were obtained via difference analysis. Univariate Cox regression analysis and construction of protein-protein interaction (PPI) networks were applied to the DEGs.Through intersection analysis of univariate COX and PPI, PLCG2 was determined as the indicator. Further analysis showed that PLCG2 expression was positively correlated with the survival of STS patients. Gene set enrichment analysis (GSEA) showed that genes in the highly expressed PLCG2 group were enriched in immune-related activities. In the low-expression PLCG2 group, genes were enriched in the E2F, G2M, and MYC pathways. Difference analysis and correlation analysis showed that CD8+ T cells, gamma delta T cells, monocytes, and M1 macrophages were positively correlated with PLCG2 expression, indicating that PLCG2 may represent the immune status of TME.Therefore, the level of PLCG2 may aid in determining the prognosis of STS patients, especially the status of TME. These data provide additional insights into the remodeling of TME.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33725976      PMCID: PMC7982206          DOI: 10.1097/MD.0000000000025008

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


  70 in total

1.  Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils.

Authors:  J E Bleasdale; N R Thakur; R S Gremban; G L Bundy; F A Fitzpatrick; R J Smith; S Bunting
Journal:  J Pharmacol Exp Ther       Date:  1990-11       Impact factor: 4.030

Review 2.  Signaling pathways in breast cancer: therapeutic targeting of the microenvironment.

Authors:  Armel Herve Nwabo Kamdje; Paul Faustin Seke Etet; Lorella Vecchio; Jean Marc Muller; Mauro Krampera; Kiven Erique Lukong
Journal:  Cell Signal       Date:  2014-08-03       Impact factor: 4.315

Review 3.  Antagonists of PD-1 and PD-L1 in Cancer Treatment.

Authors:  Evan J Lipson; Patrick M Forde; Hans-Joerg Hammers; Leisha A Emens; Janis M Taube; Suzanne L Topalian
Journal:  Semin Oncol       Date:  2015-06-10       Impact factor: 4.929

4.  Adaptive immunity maintains occult cancer in an equilibrium state.

Authors:  Catherine M Koebel; William Vermi; Jeremy B Swann; Nadeen Zerafa; Scott J Rodig; Lloyd J Old; Mark J Smyth; Robert D Schreiber
Journal:  Nature       Date:  2007-11-18       Impact factor: 49.962

5.  Peptidoglycan and lipopolysaccharide activate PLCgamma2, leading to enhanced cytokine production in macrophages and dendritic cells.

Authors:  Daisuke Aki; Yasumasa Minoda; Hideyuki Yoshida; Satoko Watanabe; Ryoko Yoshida; Giichi Takaesu; Takatoshi Chinen; Toshiya Inaba; Masaki Hikida; Tomohiro Kurosaki; Kazuko Saeki; Akihiko Yoshimura
Journal:  Genes Cells       Date:  2008-02       Impact factor: 1.891

6.  Immune cell infiltration-based signature for prognosis and immunogenomic analysis in breast cancer.

Authors:  Shiyuan Wang; Qi Zhang; Chunlu Yu; Yiyin Cao; Yongchun Zuo; Lei Yang
Journal:  Brief Bioinform       Date:  2021-03-22       Impact factor: 11.622

7.  Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.

Authors:  Maud Toulmonde; Nicolas Penel; Julien Adam; Christine Chevreau; Jean-Yves Blay; Axel Le Cesne; Emmanuelle Bompas; Sophie Piperno-Neumann; Sophie Cousin; Thomas Grellety; Thomas Ryckewaert; Alban Bessede; François Ghiringhelli; Marina Pulido; Antoine Italiano
Journal:  JAMA Oncol       Date:  2018-01-01       Impact factor: 31.777

8.  Construction of an Immunogenomic Risk Score for Prognostication in Colon Cancer.

Authors:  Han Zhang; Chuan Qin; Hua Gan; Xiong Guo; Li Zhang
Journal:  Front Genet       Date:  2020-05-21       Impact factor: 4.599

Review 9.  Immune Prophets of Lung Cancer: The Prognostic and Predictive Landscape of Cellular and Molecular Immune Markers.

Authors:  Ivana Catacchio; Anna Scattone; Nicola Silvestris; Anita Mangia
Journal:  Transl Oncol       Date:  2018-05-03       Impact factor: 4.243

10.  Identification and validation of stromal-tumor microenvironment-based subtypes tightly associated with PD-1/PD-L1 immunotherapy and outcomes in patients with gastric cancer.

Authors:  Qianqian Ren; Peng Zhu; Hui Zhang; Tianhe Ye; Dehan Liu; Zhao Gong; Xiangwen Xia
Journal:  Cancer Cell Int       Date:  2020-03-24       Impact factor: 5.722

View more
  3 in total

1.  Endothelial Phospholipase Cγ2 Improves Outcomes of Diabetic Ischemic Limb Rescue Following VEGF Therapy.

Authors:  Yashika Rustagi; Ahmed S Abouhashem; Priyanka Verma; Sumit S Verma; Edward Hernandez; Sheng Liu; Manishekhar Kumar; Poornachander R Guda; Rajneesh Srivastava; Sujit K Mohanty; Sedat Kacar; Sanskruti Mahajan; Kristen E Wanczyk; Savita Khanna; Michael P Murphy; Gayle M Gordillo; Sashwati Roy; Jun Wan; Chandan K Sen; Kanhaiya Singh
Journal:  Diabetes       Date:  2022-05-01       Impact factor: 9.337

Review 2.  Emerging Biomarkers and the Changing Landscape of Small Cell Lung Cancer.

Authors:  Anna Keogh; Stephen Finn; Teodora Radonic
Journal:  Cancers (Basel)       Date:  2022-08-03       Impact factor: 6.575

3.  Identification of N6-methylandenosine related lncRNA signatures for predicting the prognosis and therapy response in colorectal cancer patients.

Authors:  Zhiyong Li; Yang Liu; Huijie Yi; Ting Cai; Yunwei Wei
Journal:  Front Genet       Date:  2022-09-30       Impact factor: 4.772

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.